Zacks Research Predicts Increased Earnings for Hologic

Key Points

• Zacks Research has raised its FY2025 earnings per share estimate for Hologic to $4.23, slightly up from the previous estimate of $4.22.
• Hologic received upgrades from several brokerages, including Argus and Citigroup, both now rating the stock as a "buy" with target prices set at $80.00.
• The company's stock currently has an average rating of "Moderate Buy" with a consensus target price of $78.00, amid increasing interest from institutional investors.

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities research analysts at Zacks Research lifted their FY2025 earnings per share estimates for shares of Hologic in a research report issued on Wednesday, September 17th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings per share of $4.23 for the year, up from their prior forecast of $4.22. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's Q4 2025 earnings at $1.09 EPS, Q1 2026 earnings at $1.06 EPS, Q4 2026 earnings at $1.14 EPS and Q2 2027 earnings at $1.19 EPS.

Several other brokerages have also weighed in on HOLX. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Argus lifted their price objective on Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Friday. Mizuho set a $75.00 price objective on Hologic in a report on Thursday, July 31st. Morgan Stanley lifted their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Finally, Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.38.

Hologic Stock Performance

HOLX traded down $1.94 during midday trading on Thursday, reaching $66.33. The company's stock had a trading volume of 8,515,121 shares, compared to its average volume of 1,762,988. The stock has a market cap of $14.75 billion, a P/E ratio of 27.52, a PEG ratio of 2.47 and a beta of 0.57. The company has a fifty day simple moving average of $66.47 and a 200 day simple moving average of $62.75. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS.

Institutional Investors Weigh In On Hologic

A number of institutional investors have recently made changes to their positions in the stock. Chung Wu Investment Group LLC acquired a new position in Hologic in the second quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 273 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in Hologic during the second quarter worth about $33,000. Zions Bancorporation National Association UT bought a new stake in Hologic during the first quarter worth about $34,000. Finally, Cromwell Holdings LLC raised its holdings in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 436 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.